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Zou Y, Hu M, Lee J, Nambiar SM, Garcia V, Bao Q, Chan JY,
Dai G. Nrf2 is essential for timely M phase entry of replicating
hepatocytes during liver regeneration. Am J Physiol Gastrointest Liver
Physiol 308: G262–G268, 2015. First published December 18, 2014;
doi:10.1152/ajpgi.00332.2014.—The transcription factor nuclear fac-
tor erythroid 2-related factor 2 (Nrf2) regulates various cellular
activities, including redox balance, detoxification, metabolism, au-
tophagy, proliferation, and apoptosis. Several studies have demon-
strated that Nrf2 regulates hepatocyte proliferation during liver regen-
eration. The aim of this study was to investigate how Nrf2 modulates
the cell cycle of replicating hepatocytes in regenerating livers. Wild-
type and Nrf2 null mice were subjected to 2/3 partial hepatectomy
(PH) and killed at multiple time points for various analyses. Nrf2 null
mice exhibited delayed liver regrowth, although the lost liver mass
was eventually restored 7 days after PH. Nrf2 deficiency did not affect
the number of hepatocytes entering the cell cycle but did delay
hepatocyte mitosis. Mechanistically, the lack of Nrf2 resulted in
increased mRNA and protein levels of hepatic cyclin A2 when the
remaining hepatocytes were replicating in response to PH. Moreover,
Nrf2 deficiency in regenerating livers caused dysregulation of Wee1,
Cdc2, and cyclin B1 mRNA and protein expression, leading to
decreased Cdc2 activity. Thus, Nrf2 is required for timely M phase
entry of replicating hepatocytes by ensuring proper regulation of
cyclin A2 and the Wee1/Cdc2/cyclin B1 pathway during liver regen-
eration.
nuclear factor erythroid 2-related factor 2; hepatocyte mitosis; hepa-
tocyte proliferation
NUCLEAR FACTOR ERYTHROID 2-related factor 2 (Nrf2) is a basic
leucine zipper region-containing transcription factor that is
abundantly expressed in many tissues such as the liver (6). The
activity of Nrf2 is regulated by multiple mechanisms, including
gene transcription, kelch-like ECH-associated protein 1-medi-
ated proteasome degradation, and kinase-mediated phosphory-
lation. The sequential events leading to Nrf2 activation include
nuclear translocation, heterodimer formation with small Maf por-
tions, binding to an antioxidant response element (ARE), and
transactivation of Nrf2 target genes. There are both direct and
indirect Nrf2 target genes involved in various cellular functions,
including detoxification, metabolism, autophagy, proliferation,
differentiation, and apoptosis (3, 13, 17, 26). Previous studies
have demonstrated that Nrf2 regulates the hepatocyte proliferative
response to liver mass loss (2, 33). The aim of the present study
was to investigate how Nrf2 modulates the cell cycle progression
of replicating hepatocytes during liver repair.
Partial hepatectomy (PH) induces highly synchronized entry
and progression of the cell cycle in residual hepatocytes. Thus,
PH is widely used as an in vivo model to study the regulation
of cell proliferation (23). We performed PH on wild-type and
Nrf2 null mice and compared the cell cycle progression of
replicating hepatocytes. Our data indicate that Nrf2 is a regu-
lator of hepatocyte mitosis.
MATERIALS AND METHODS
Mice and PH. The animals used for this study were wild-type and
Nrf2-deficient male mice (3 mo old) with a C57BL6/129SV mixed
background (6). The mice were housed in plastic cages at 22  1°C
on a 12:12-h light-dark cycle with lights on from 6:00 A.M. to 6:00
P.M. Standard rodent chow and water were provided ad libitum
throughout the entire feeding period. A standard 70% PH was per-
formed between 10:00 A.M. and 12:00 P.M. according to the proce-
dure described previously (7, 12). The gall bladders were kept intact.
All of the animal experiments were conducted in accordance with the
National Institutes of Health Guide for the Care and Use of Labora-
tory Animals. The protocols for the care and use of animals were
approved by the Indiana University-Purdue University Indianapolis
Animal Care and Use Committee.
Immunohistochemistry. Formalin-fixed and paraffin-embedded
liver sections were subjected to standard immunohistochemistry.
Ki-67 immunostaining was performed to visualize and count the
proliferating hepatocytes. Hematoxylin- and eosin-stained liver sec-
tions were used to quantify mitotic figures in hepatocytes. The
Ki-67-positive hepatocytes and mitotic figures were counted in five
randomly chosen microscope fields per section at 200 and 100
magnifications, respectively.
Western blot analysis. Liver homogenates (10 or 30 g) were
separated by polyacrylamide gel electrophoresis under reducing con-
ditions. The proteins were then electrophoretically transferred to
polyvinylidene difluoride membranes. The following antibodies were
used as probes: cyclin D1 (no. 2922) and cyclin B1 (no. 4138) (Cell
Signaling Technology, Danvers, MA); cyclin A2 (1540-1) and
NQO-1 (2618-1) (Epitomics, Burlingame, CA); cyclin E1 (SC-481),
Wee1 (SC-9037), p-Cdc2 p34 (Tyr15) (SC-7898), Cdc2 p34 (SC-54),
and glyceraldehyde 3-phosphate dehydrogenase (SC-25778) (Santa
Cruz Biotechnology, Santa Cruz, CA). The immune complexes were
detected using an enhanced chemiluminescence system (Pierce, Rock-
ford, IL).
Quantitative real-time polymerase chain reaction. TRIzol reagent
was used to prepare total RNA from frozen liver tissue according to
the manufacturer’s protocol (Invitrogen, Carlsbad, CA). The cDNAs
were synthesized from total RNA (1 g) of each sample using a Verso
cDNA Kit (Thermo Scientific). The cDNAs were diluted four times
with water and subjected to quantitative real-time polymerase chain
reaction to quantify mRNA levels. TaqMan Universal PCR Master
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Mix, primers, and TaqMan MGB probes of mouse cyclin A2
(Mm00438063_m1), cyclin B1 (Mm03053893_gh), Cdc2
(Mm00772472_m1), Wee1 (Mm00494175_ml), and -actin
(Mm00607939_s1) were purchased from Applied Biosystems (Fos-
ter City, CA). The amplification reactions were performed with the
ABI Prism 7900 sequence detection system (Applied Biosystems)
with initial hold steps (50°C for 2 min followed by 95°C for 10 min)
and 40 cycles of a two-step PCR (92°C for 15 s and 60°C for 1 min).
The comparative CT method was used for the relative quantification of
the amount of mRNA in each sample. The data were normalized to the
-actin transcript levels.
Transient transfection and luciferase reporter activity assay.
Hepa-1 cells were cultured in Dulbecco’s modified Eagle’s medium
(Mediatech) supplemented with 10% fetal bovine serum (Biomeda) at
37°C in a 5% CO2 atmosphere. The cells were plated in 24-well plates
at 1  105 cells/well. After overnight culture, FuGENE6 (Promega,
Madison, WI) was used to transfect a mcyclin A2-Luc construct (300
ng/well) harboring a firefly luciferase reporter driven by a 700-bp
5=-flanking fragment of mouse cyclin A2 gene (kindly provided by Dr.
Jean Marine Blanchard, University of Montpellier, Montpellier,
France) and a mouse Nrf2 expression plasmid (50 ng/well) or a
balance plasmid (pGL-3 basic vector, 50 ng/well). A Renilla lu-
ciferase expression vector (10 ng/well) was cotransfected as an inter-
nal control for normalization of transfection efficiency. A hHO1ARE-
Luc reporter construct (300 ng/well) containing six copies of an
antioxidant response element (ARE) identified in the human heme
oxygenase 1 gene was used as a positive control reporter. The cells
were harvested 48 h after treatment, and then firefly and Renilla
luciferase activities were measured using the Dual Luciferase Re-
porter Assay System (Promega).
Cdc2 kinase activity assay. Cdc2 protein was immunoprecipitated
from each liver lysate, and the kinase activity was determined by a
kinase assay kit. Briefly, each liver sample was homogenized in a lysis
buffer (T-PER Tissue Protein Extraction Reagent; Thermo Scientific)
containing a protease and phosphatase inhibitor cocktail (Halt Pro-
tease & Phosphatase Inhibitor Single-Use Cocktail; Pierce) and incu-
bated on ice for 30 min. The homogenate was centrifuged at 10,000 g
for 10 min at 4°C. The protein concentration of the supernatant was
measured with Pierce 660 nm Protein Assay Reagent (Thermo Sci-
entific). A portion of the supernatant containing 100 g of liver
protein was adjusted to 300 l with PBS and incubated with 20 l of
agarose-conjugated mouse monoclonal anti-Cdc2 antibody (SC-54
AC; Santa Cruz Biotechnology) with gentle shaking overnight at 4°C.
The immunoprecipitate was collected by centrifugation at 1,000 g and
washed with 1 ml of PBS four times. Cdc2 kinase activity was
evaluated with the Cdc2-cyclin B kinase assay kit according to the
manufacturer’s instructions (CycLex, Nagano, Japan). The average
value for wild-type mice at 24 h after PH was set to one.
Statistical analysis. The data are shown as means  SD. All
statistical analyses were performed using a one-way analysis of
variance. The comparisons of means were determined by post hoc
analysis. Significant differences were defined when P  0.05.
RESULTS
Nrf2 deficiency causes the impairment of liver regrowth.
Mice lacking Nrf2 have a reduced liver size and a lower
liver-to-body weight ratio than wild-type mice (4.52 0.09 vs.
4.91  0.10; P  0.05). This observation is consistent with
previous reports (2, 15). After 70% PH, the remaining livers in
each genotype of mice regenerated to the original liver mass
(Fig. 1).1 In wild-type mice, each wave of hepatocyte replica-
tion drove a further increase in the liver mass. Thus, the
regenerating livers exhibited a gradual and consistent increase
from 44 h (the first peak of hepatocyte mitosis) to 116 h (the
last peak of hepatocyte mitosis) after PH. However, Nrf2
knockout mice showed a sluggish liver regrowth pattern com-
pared with wild-type mice. The liver regrowth in Nrf2 mutants
was reduced at 60 h but normal at 68 h. Additionally, the
mutants had reduced liver growth again at 92 h but normal liver
size at 96 h after PH. Thus, the Nrf2-deficient mice exhibited
an impaired regenerative response to liver mass loss. The
results indicate that Nrf2 is required for the normal progression
of liver regeneration.
The lack of Nrf2 results in a delay in hepatocyte mitosis
during the first wave of hepatocyte replication following PH.
PH-induced liver regeneration consists of four consecutive
waves of hepatocyte replication that are indicated by four
rhythmic mitosis peaks (36). We first evaluated the numbers of
Ki-67-positive hepatocytes at various time points after PH in
the two genotypes of mice. This assessment allowed us to
determine whether the absence of Nrf2 affects the total number
of hepatocytes undergoing each wave of the cell cycle because
Ki-67 is expressed in each active phase of the cell cycle. We
observed that there were significantly fewer proliferative
hepatocytes at 92 h after PH in Nrf2 null mice than in their
wild-type littermates (Fig. 2A). This result indicates that the
Nrf2 null mutation inhibits hepatocyte replication during the
third wave of the hepatic proliferative cycle (84 –108 h
post-PH).
To investigate cell cycle progression, we counted bromode-
oxyuridine (BrdU)-positive (S phase) hepatocytes at 36 h
following PH. At this time point, DNA synthesis peaks during
the first and major wave of hepatocyte proliferation in PH-
induced liver regeneration (7, 10, 21, 23, 36). Thus, a signifi-
cant difference in the numbers of hepatocytes undergoing DNA
synthesis was not observed when the two strains of mice were
compared (Fig. 2, B and C). These data demonstrate that Nrf2
deficiency does not significantly affect S phase entry and
1 The data generated from wild-type mice in Figs. 1, 2A, and 3A have been
published and are reused as wild-type controls in the current study (36). The
wild-type mice and Nrf2 null mice have the same genetic background.
Fig. 1. Liver regrowth following partial hepatectomy (PH) in nuclear factor
erythroid 2-related factor 2 (Nrf2)-sufficient (/) and -deficient (Nrf2	/	)
mice. Mice were subjected to PH and killed at the indicated time points.
Liver-to-body weight ratios were used as a liver regrowth index. D, day.
Results are presented as the mean liver-to-body weight ratios  SD (n 
 3–5
mice/time point for each genotype; *P  0.05).
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progression in replicating hepatocytes during the first round of
the cell cycle after PH.
We then evaluated the numbers of hepatocytes undergoing
mitosis (M phase hepatocytes) throughout the course of liver
regrowth by quantifying hepatocyte mitotic figures. As shown
in Fig. 3, during the first wave of hepatocyte replication
(24–60 h after PH), the number of mitotic hepatocytes in Nrf2
null mutants was approximately half of that in wild types at 44
Fig. 2. Nos. of proliferating hepatocytes after PH in Nrf2/
and Nrf2	/	 mice. Mice were subjected to PH and killed at the
indicated time points. A: assessment of total proliferating hepa-
tocytes. Ki-67 immunostaining was performed with liver sec-
tions. Ki-67-positive hepatocytes were counted at 200 mag-
nification in 5 randomly chosen fields/section. Results are
shown as the means per field  SD (n 
 3–5 mice/time point
for each genotype; *P  0.05). B and C: no. of hepatocytes
undergoing DNA synthesis at 36 h after PH. Mice were killed
at 36 h post-PH. One hour before death, bromodeoxyuridine
(BrdU) was injected (100 mg/kg ip). Liver sections were
subjected to BrdU immunostaining. B: representative liver
sections show BrdU-positive hepatocytes. C: BrdU-positive
hepatocytes were counted at100 magnification in 5 randomly
chosen fields/section. Data are shown as the means per field 
SD (n 
 3–5 mice/time point for each genotype).
Fig. 3. Nos. of hepatocytes undergoing mitosis after PH in Nrf2/ and Nrf2	/	 mice. Mice were subjected to PH and killed at the indicated time points. Liver
sections were stained with hematoxylin and eosin. A: hepatocytes and hepatic mitotic figures were counted at 100 magnification in 5 randomly chosen
fields/liver section. Data are shown as the means of the nos. of mitotic hepatocytes/100 hepatocytes  SD (n 
 3–5 mice/time point for each genotype; *P 
0.05). B: representative liver sections showing mitotic figures in hepatocytes at the indicated time points following PH.
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h. The number of mitotic hepatocytes subsequently became
comparable with the wild type at 48 h. These data indicate that
the lack of Nrf2 causes a delay in hepatocyte mitosis during the
initial and strongest wave of hepatocyte replication. As the
liver regeneration progressed through the remaining three he-
patocyte proliferative cycles, the M phase hepatocytes were
significantly reduced in Nrf2 nulls compared with wild types at
92 h following PH. This finding is consistent with the Ki-67
assessment at the same time point (Fig. 2A). Thus, without
Nrf2, the third wave of hepatocyte proliferation (84–108 h
after PH) was suppressed.
Nrf2 activity progressively increases during liver re-
generation. NAD(P)H-quinone oxidoreductase 1 (NQO-1) is a
typical target gene of Nrf2 (5). During liver injury, both the
mRNA and protein expression of the gene is solely regulated
by Nrf2 (1). Thus, we evaluated hepatic NQO-1 protein ex-
pression to estimate the activity of Nrf2 in regenerating livers
(Fig. 4A). The result showed that, in wild-type mice, the
protein level of hepatic NQO-1 gradually increased as liver
regrowth progressed. In contrast, the protein was only weakly
detected in both resting and regenerating livers in Nrf2 null
mice. This observation indicates that Nrf2 activity is gradually
upregulated, suggesting that progressively increased Nrf2 ac-
tivity may be required for sustained liver regeneration. In
addition, our data further prove that NQO-1 is a reliable marker
for Nrf2 activity because the loss of Nrf2 results in almost
diminished NQO-1 expression when the liver undergoes a
variety of biological changes in response to PH.
Nrf2 absence leads to the dysregulation of a subset of cell
cycle components in regenerating livers. We analyzed the
protein expression of major cell cycle components in regener-
ating livers in wild-type and Nrf2 null mice to evaluate the
impact of Nrf2 ablation on hepatocyte proliferation at the
molecular level. As observed in Fig. 4A, the lack of Nrf2
affected the levels but not the protein expression kinetics of
hepatic cyclins D1, A2, and E1. Most notably, Nrf2 null
mutants accumulated more cyclin A2 protein at 36 h following
PH than wild types. This observation suggests that Nrf2 plays
an inhibitory role in the initiation of cyclin A2 protein expres-
sion and thus that the absence of Nrf2 leads to increased cyclin
A2 protein synthesis in regenerating livers.
We next quantified the mRNA expression of hepatic cyclin
A2 during the first wave of hepatocyte replication to determine
whether the Nrf2-dependent dysregulation of cyclin A2 expres-
sion occurs at the mRNA level. As shown in Fig. 4B, the
level of cyclin A2 mRNA peaked at 36 h after PH in Nrf2
null livers but at 44 h in wild-type regenerating livers. The
data indicate a stronger initiation of cyclin A2 transcription
in cells lacking Nrf2. This result is consistent with the
observation at the protein level. Furthermore, a transient
transfection assay showed that overexpression of Nrf2 re-
duced the activity of the mouse cyclin A2 promoter (Fig.
4C). Collectively, these data demonstrate that Nrf2 is a
transcriptional suppressor of cyclin A2.
Nrf2 null mutation causes the dysregulation of the Wee1/
Cdc2/cyclin B1 pathway during the first round of hepatocyte
replication after PH. The appropriate regulation of the Wee1/
Cdc2/cyclin B1 pathway is crucial for a normal G2/M transi-
tion during the cell cycle. Increased phosphorylation of Cdc2 at
Tyr15 by Wee1 kinase reduces the activity of Cdc2/cyclin B
complex and leads to the inhibition of M phase entry (11).
During liver regeneration, this pathway regulates the timing of
mitosis in replicating hepatocytes (22). Therefore, we postu-
lated that the dysregulation of this pathway may cause the
delayed M phase entry of proliferating hepatocytes lacking
Nrf2. To address this hypothesis, we first examined the mRNA
and protein expression of the components in this pathway in
the resting and regenerating livers of wild-type and Nrf2 null
mice. We found that Wee1, Cdc2, and cyclin B1 were altered
at both the mRNA and protein levels when Nrf2 was absent
(Fig. 5, A and B). Moreover, the lack of Nrf2 led to the
hyperphosphorylation of Cdc2 protein at 36 and 44 h after PH,
which is consistent with the excessive accumulation of Wee1
caused by Nrf2 deficiency. The data demonstrate that Nrf2
deficiency results in the dysregulation of Wee1, Cdc2, and
cyclin B1. These findings prompted us to analyze the activity
of Cdc2 in the regenerating livers of both genotypes of mice.
We found that Nrf2 absence caused a significant decrease in
Cdc2 activity during hepatocyte mitosis (44 h following PH)
(Fig. 5C). Thus, these data link the dysregulated Wee1/Cdc2/
cyclin B1 pathway and decreased Cdc2 activity to delayed
mitosis during liver regeneration in Nrf2 null mice.
DISCUSSION
The current study demonstrates that Nrf2 is a novel
regulator of hepatocyte mitosis during liver regeneration.
We found that the absence of Nrf2 does not affect S phase
entry and progression but entry into M phase in regenerating
hepatocytes. Mechanistically, we revealed that Nrf2 is in-
dispensable for the proper regulation of cyclin A2 and the
Wee1/Cdc2/cyclin B1 pathway during liver regeneration. As
reported in our previous publication, the absence of Nrf2
leads to increased levels of cyclin A2 mRNA and protein in
the maternal liver exhibiting hepatocyte proliferation during
gestation, which demonstrates that Nrf2 is a cyclin A2
transcriptional suppressor (37). In this study, we found that
Nrf2 deficiency results in elevated cyclin A2 mRNA and
protein expression in the regenerating liver. Our previous
and current findings collectively indicate that Nrf2 may
function as a brake to prevent the overactivation of cyclin
A2 transcription and translation when hepatocytes go
through the cell cycle. It was previously demonstrated that
timely degradation of cyclin A is a key event in M phase
progression because nondegradable mutations in cyclin A
result in cell arrest in metaphase (29, 32). Thus, the delayed
mitosis in replicating hepatocytes caused by Nrf2 null mu-
tation is at least partially due to the excessive accumulation
of cyclin A2. Moreover, we found that Nrf2 genetic deletion
dysregulates the components of the Wee1/Cdc2/cyclin B1
pathway. When Nrf2 is absent, each component in this
pathway is abnormally regulated at the mRNA and/or pro-
tein level. These pathway alterations lead to an increased
amount of Wee1 kinase, hyperphosphorylation of its sub-
strate Cdc2 at Tyr15, and reduced Cdc2 activity. It has been
well established that the activity of the Cdc2/cyclin B
complex is essential for M phase entry (11). Thus, the
dysregulation of this pathway also contributes to the delayed
mitosis in hepatocytes lacking Nrf2. Collectively, these data
demonstrate that Nrf2 modulates cell cycle progression in
regenerating hepatocytes by ensuring the appropriate regu-
lation of cyclin A2 and the Wee1/Cdc2/cyclin B1 pathway.
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Nrf2 is highly activated in various tumor cells and promotes
their proliferation through poorly understood mechanisms (31).
Evidence shows that Nrf2 may increase K-Ras-induced prolif-
eration and tumorigenesis (9). Moreover, Nrf2 regulates met-
abolic reprogramming by redirecting glucose and glutamine
into anabolic pathways in cancer cells to support cancer cell
proliferation (27). Future studies must determine whether these
Nrf2-dependent mechanisms also operate during normal hepa-
tocyte replication, or vice versa, whether Nrf2 regulates cyclin
A2 and the Wee1/Cdc2/cyclin B pathway in tumor cells. Of
note, Nrf2 null mice are highly susceptible to chemical-in-
duced carcinogenesis (16, 19, 30, 34). The misregulation of
mitotic entry is often oncogenic (35). Therefore, it is possible
that the regenerative response to chemical-induced tissue in-
jury in cells deficient in Nrf2 prevents timely M phase entry,
which promotes tumor formation.
Previous reports and our findings indicate that Nrf2 plays
multiple roles in a stage-dependent manner during liver regen-
eration. It has been shown that Nrf2 absence increases NF-kB
activation, reduces insulin signaling, and enhances hepatocyte
apoptosis in regenerating livers at 3 and/or 6 h after PH. The
previous study has also reported aggravated steatosis at 48 h
post-PH; aberrant numbers of S phase hepatocytes at 48, 72,
and 120 h; and elevated oxidative stress at 72 h in Nrf2 null
regenerating livers (2). Notch1 and the augmenter of liver
regeneration have been identified as Nrf2 direct target genes in
regenerating livers (8, 33). Additionally, the Sestrin2-mediated
Nrf2, mTOR, and p53/p21 signaling network has been pro-
posed to regulate hepatocyte proliferation in response to liver
injury (4). We recently reported that Nrf2 is required to
maintain newly regenerated hepatocytes in a fully differenti-
ated state. We found that the lack of Nrf2 causes transient but
massive impairment in hepatocyte identity 60 h following PH,
which is indicated by marked reduction in hepatocyte volume
and strong activation of progenitor marker gene expression
(38). This observation may suggest a phenomenon of hepato-
cyte dedifferentiation caused by Nrf2 absence, which corre-
lates with liver regrowth inhibition at the same time point after
PH in Nrf2 null mice (Fig. 1). In this study, we found that Nrf2
deficiency results in a delay in hepatocyte mitosis due to
dysregulation of cyclin A2 and the Wee1/Cdc2/cyclin B1
pathway during the first wave of hepatocyte replication follow-
ing PH. Moreover, we also found that Nrf2 activity is gradually
increased during liver regeneration (Fig. 4A). This may be
induced by elevated oxidative stress at later stages of liver
regeneration (2) and might be required to maintain hepatocytes
in a differentiated state during the post-PH remodeling period
(38). This hypothesis should be tested in future studies. Col-
lectively, these studies demonstrate the requirement of Nrf2 for
normal liver regeneration. However, Nrf2 activation exerts
negative effects on liver regeneration. Weiner’s group gener-
ated transgenic mice restricting the expression of an Nrf2
mutant lacking the Keap1 binding domain in hepatocytes (20).
Using this mouse model, the authors demonstrated that consti-
tutive activation of Nrf2 results in a delay in hepatocyte
proliferation and an increase in hepatocyte apoptosis within 72
h after PH without affecting the final restoration of the lost
liver mass. Mechanistically, this is due to temporary upregu-
lation of the expression of the Nrf2 direct target genes p15 and
Bcl2l11. Our recent report demonstrates that Nrf2 is not
activated when hepatocytes undergo the first round of replica-
Fig. 4. A: protein expression of a subset of cell cycle components in regener-
ating livers of Nrf2/ and Nrf2	/	 mice. Livers were collected from normal
mice and mice subjected to PH at the indicated time points after surgery. Liver
lysates prepared from 3 mice/time point for each genotype were pooled with
equal amounts of proteins from each preparation. Western blotting was
performed with antibodies against the proteins indicated. Glyceraldehyde
3-phosphate dehydrogenase (GAPDH) was used as a loading control. NL,
normal liver. B: mRNA expression of cyclin A2 in regenerating livers. Total
RNA was prepared from the livers at the indicated time points after PH.
Hepatic mRNA levels of cyclin A2 were measured by quantitative real-time
polymerase chain reaction (qRT-PCR) and are expressed as the mean fold
change relative to the mRNA level at 24 h post-PH in Nrf2/ mice  SD
(n 
 3 mice/time point for each genotype; *P  0.05 between Nrf2/ and
Nrf2	/	 mice). C: Nrf2 negatively regulates cyclin A2 transcription. A Nrf2
expression vector (mNRF2) and a mouse cyclin A2 promoter reporter con-
struct (mcyclinA2-Luc) or a construct containing 6 copies of an antioxidant
response element (ARE) of human heme oxygenase 1 gene (hHO1ARE-Luc,
positive control) were cotransfected into Hepa-1 cells as described in
MATERIALS AND METHODS. Note that Nrf2 overexpression increased the activity
of the ARE in hHO1ARE-Luc but reduced the activity of the mouse cyclin A2
promoter. Data are representative results from 3 independent experiments.
*P  0.05.
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tion following PH. In addition, Keap1 knockdown-induced
Nrf2 activation disrupts the redox cycle and hepatocyte cell
cycle progression in the regenerating liver (14). Clearly, Nrf2
activity needs to be tightly controlled during liver regeneration
because both overly activated and deficient Nrf2 activity im-
pairs the hepatic regenerative response. The results from stud-
ies concerning the roles for Nrf2 in liver regeneration support
the notion that Nrf2 functions as “a double-edge sword” in
distinct pathological states (24, 31).
PH induces sequential proliferation of hepatic parenchyma
and nonparenchyma cells, dynamic adjustments in hepatocyte
size, liver progenitor cell activation, and hepatic tissue remod-
eling (18, 25, 28, 38). Liver-to-body weight ratio is widely
used as a parameter for general assessment of liver size or
regrowth following PH. We found that genetic deletion of Nrf2
caused inhibition of liver regrowth at multiple time points
post-PH (Fig. 1). We recently reported that the lack of Nrf2
leads to reductions in hepatocyte size at 60 h (day 2.5) and 140
h (day 6) after PH (38). This observation can explain the
decreases in liver-to-body weight ratio at the same time points
following PH (Fig. 1). Furthermore, we observed that Nrf2
absence caused a decrease in hepatocyte proliferation at 92 h
after PH (Figs. 2 and 3), which should contribute to concurrent
suppression in liver regrowth (Fig. 1). However, Nrf2 null
mice exhibited lower liver-to-body weight ratios at several
additional time points (12, 72, 84, and 168 h) post-PH without
significant differences in hepatocyte volume and proliferation
compared with wild-type controls (Fig. 1) (38). The data
suggest uncovered roles for Nrf2 during liver regeneration that
need to be explored in future studies.
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Fig. 5. A: protein expression of Wee1, Cdc2, and cyclin B1 in regenerating livers of Nrf2/ and Nrf2	/	 mice. The same set of protein samples described in
Fig. 4A was used for Western blotting with antibodies against the proteins indicated. GAPDH was used as a loading control. B: mRNA expression of Wee1, Cdc2,
and cyclin B1 in regenerating livers of Nrf2/ and Nrf2	/	 mice. The same set of total RNA samples described in Fig. 4B was used. Hepatic mRNA levels
of Wee1, Cdc2, and cyclin B1 were measured by qRT-PCR and are expressed as the mean fold change relative to mRNA levels at 24 h post-PH in Nrf2/
mice  SD (n 
 3 mice/time point for each genotype; *P  0.05 between Nrf2/ and Nrf2	/	 mice). C: Cdc2 kinase activity in regenerating livers of Nrf2/
and Nrf2	/	 mice. Liver lysates were prepared from both genotypes of mice at the indicated time points following PH. A Cdc2 kinase activity assay was
performed as described in MATERIALS AND METHODS. The average value for Nrf2/ mice at 24 h after PH was set to 1. Results are presented as the mean fold
change relative to data at 24 h post-PH in Nrf2/ mice  SD (n 
 3 mice/time point for each genotype; *P  0.05 between Nrf2/ and Nrf2	/	 mice).
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